BioSig Technologies, Inc. - BSGM STOCK NEWS

Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.

BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.

BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.

Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.

Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.

For more information and the latest updates, visit the SEC's website.

04/04/2024 11:35 AM

News

BioSig Engages Consulting Firm for Business Model Strategies

Rhea-AI Summary

BioSig Technologies, Inc. appoints Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies, aiming to transform the company's future course by implementing solutions to address operational and financial deficits.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.39%

Tags

02/20/2024 10:00 AM

News

BioSig Announces Reduction of its Workforce

Rhea-AI Summary

BioSig Technologies, Inc. (BSGM) announced a significant reduction in employees and business operations.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-15.78%

Tags

02/06/2024 08:30 AM

News

BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the successful adoption of its Near Field Tracking (NFT) algorithm, which has reduced ablation time by approximately 66%. Physicians have completed over 100 cases with the NFT algorithm, providing tissue-specific feedback and color-coded characterization in real time. The software has been leveraged at major medical centers and health systems, receiving positive feedback from leading cardiac electrophysiologists. This innovative feature is expected to significantly improve procedural efficiency and accuracy in cardiac ablation procedures.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-21.05%

Tags

01/31/2024 11:15 AM

News

BioSig Announces Reverse Stock Split

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) will undergo a reverse stock split at a ratio of 1 post-split share for every 10 pre-split shares, effective February 2, 2024. The reverse stock split will reduce the outstanding shares from 93,344,435 to approximately 9,334,636. The new CUSIP number for the common stock following the reverse stock split will be 09073N3008.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.64%

Tags

01/30/2024 08:30 AM

News

BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) announced a workforce reduction to reduce annual cash burn by 50%. The company is shifting its business model to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform. The platform's NFT algorithm has shown a 66% reduction in ablation time, and the company is looking to expand its applications and quantify the efficacy and safety benefits of NFT.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12.96%

Tags

12/06/2023 02:20 PM

News

BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024

Rhea-AI Summary

BioSig Technologies, Inc. (Nasdaq: BSGM) issued its 2023 letter to shareholders, highlighting recent achievements and insights.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.02%

Tags

11/13/2023 04:30 PM

News

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the closing of a registered direct offering, issuing 6,996,922 shares of common stock, Series A and Series B warrants. The offering was priced at $0.3573 per share, with gross proceeds of approximately $2.5 million. H.C. Wainwright & Co. acted as the exclusive placement agent. The net proceeds will be used for working capital and general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.99%

Tags

11/09/2023 08:00 AM

News

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) announces a registered direct offering of 6,996,922 shares of its common stock, Series A and Series B warrants at $0.3573 per share, with H.C. Wainwright & Co. as the exclusive placement agent.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.64%

Tags

11/07/2023 08:00 AM

News

BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) appoints Frederick Hrkac, a 32-year medical device industry veteran, as Executive Vice President. His extensive experience includes leading Johnson & Johnson's cardiology/electrophysiology business to a $500M revenue and facilitating a $1B sale of a medical device company in 2018.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.87%

Tags

11/02/2023 08:00 AM

News

BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care

Rhea-AI Summary

BioSig Technologies, Inc. announced that Mayo Clinic-Phoenix has upgraded to the PURE EP™ Platform's subscription model to access the latest advancements in cardiac arrhythmia identification. The new software features include Automatic Tachycardia Characterization (ATC) and Near-Field Tracking (NFT) to assist electrophysiologists in ablation procedures. Mayo Clinic-Phoenix is ranked as the number one hospital in Arizona and is now part of the PURE EP™ subscriber community, along with Cleveland Clinic.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.22%

Tags

FAQ

What is the current stock price of BioSig Technologies (BSGM)?

The current stock price of BioSig Technologies (BSGM) is $1.87 as of November 20, 2024.

What is the market cap of BioSig Technologies (BSGM)?

The market cap of BioSig Technologies (BSGM) is approximately 32.4M.

What does BioSig Technologies, Inc. do?

BioSig Technologies, Inc. is a medical technology company specializing in advanced digital signal processing technology for the electrophysiology market. Their flagship product, PURE EP™ Platform, enhances intracardiac signal visualization and facilitates targeted cardiac ablation procedures.

What is the PURE EP™ Platform?

The PURE EP™ Platform is an FDA-cleared, non-invasive class II medical device that combines hardware and software to provide real-time, high-clarity visualization of intracardiac signals, aiding in efficient and precise cardiac ablation procedures.

Who are BioSig's collaborators?

BioSig collaborates with leading healthcare institutions such as the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute to improve the efficacy and efficiency of electrophysiology procedures.

What recent achievements has BioSig made?

Recent achievements include the introduction of the Near-Field Tracking (NFT) algorithm, which has significantly reduced ablation time by 66%, and the appointment of Bridge Associates International Pharmaceutical Consulting to advise on business strategies.

How is BioSig addressing its financial and operational challenges?

BioSig has implemented workforce reductions and strategic shifts to reduce cash burn and is actively seeking partnerships for sales distribution and clinical support. The company is also exploring AI-driven opportunities for its product portfolio.

What are BioSig's future plans?

BioSig plans to expand the clinical adoption of its PURE EP™ Platform, explore new AI-driven market opportunities, and continue improving shareholder value under its new leadership and Board of Directors.

How does the NFT algorithm benefit clinical procedures?

The Near-Field Tracking (NFT) algorithm provides tissue-specific feedback and color-coded characterization in real-time, which improves procedural efficiency and accuracy, thereby reducing ablation time and enhancing patient outcomes.

Is BioSig publicly traded?

Yes, BioSig Technologies, Inc. is publicly traded on the Nasdaq Capital Market under the ticker symbol BSGM.

What steps has BioSig taken to comply with Nasdaq requirements?

BioSig has addressed compliance issues with the Nasdaq Hearings Panel and implemented a reverse stock split to meet the minimum bid price requirement.

Where can I find more information about BioSig?

More information about BioSig Technologies, Inc. can be found on the SEC's website at http://www.sec.gov, as well as on their official investor relations page.